Coronavirus Vaccine / University of Alberta - LARVOL DELTA

Mixed lipopeptide-based mucosal vaccine candidate induces cross-variant immunity and protects against SARS-CoV-2 infection in hamsters. (PubMed, Immunohorizons) - "We have designed a lipopeptide-based, mucosal, pan-coronavirus vaccine candidate, derived from highly conserved and/or functional regions of the SARS-CoV-2 spike, nucleocapsid, and membrane proteins...Finally, the lipopeptide-based intranasal vaccine demonstrated significant improvement in lung pathologies in a hamster model of SARS-CoV-2 infection. These studies are fundamentally important and open new avenues in the investigation of an innovative, broadly protective intranasal vaccine platform for SARS-CoV-2 and its variants."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Heterologous immunity induced by 1 generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. (PubMed, Front Immunol) - "In addition, many unexposed individuals have been found to harbor T cells that are cross-reactive against SARS-CoV-2 antigens, with a possible protective role. In this review, we will discuss various aspects of natural or vaccine-induced heterologous (cross-reactive) adaptive immunity against SARS-CoV-2 and other coronaviruses, and their role in achieving the concept of a pan-coronavirus vaccine."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases